Atopic dermatitis: Tofacitinib, an option for refractory disease
Sineida Berbert Ferreira, Rachel Berbert Ferreira, Morton Scheinberg
Abstract
Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate-severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.
Topics & Concepts
TofacitinibMedicineAtopic dermatitisRefractory (planetary science)DermatologyDiseaseQuality of life (healthcare)Internal medicineRheumatoid arthritisAstrobiologyNursingPhysicsDermatology and Skin DiseasesPharmacological Effects of Natural CompoundsUrticaria and Related Conditions